US › Healthcare

Black Diamond Therapeutics Inc (BDTX)

US · Healthcare · Biotechnology

$1.93-0.52%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-9.9M

EPS

$-0.17

EPS estimate

$-0.18

EPS came in at -0.17 against a street estimate of -0.18 — a beat of 5.6%.

Key statistics

Market cap

$112.3M

Forward P/E

8.3

P/B

1.25

Book value

$1.67

EPS (TTM)

$-0.70

52-week high

$4.94

52-week low

$1.60

50-day MA

$1.96

200-day MA

$2.38

Beta

3.31

Analyst view

Analysts rate Black Diamond Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $10.00.

Shareholding

Insiders

0.65%

Institutions

72.52%

Largest institutional holders

Fund	Stake
T. Rowe Price Investment Management,Inc.	18.39%
NEA Management Company, LLC	7.74%
Acadian Asset Management LLC	4.09%
Vanguard Capital Management, LLC	3.22%
Defilade Capital Management, L.P.	2.92%
Renaissance Technologies Corp	2.86%
Dimensional Fund Advisors, Inc.	2.38%
BlackRock Inc	1.93%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Black Diamond Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.